Allergic Rhinitis
📧 Sign up to get email alerts when something new happens for Allergic Rhinitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-11-15FDA Approved: FLONASE SENSIMIST ALLERGY RELIEF — Supplemental Application (Haleon US Holdings LLC)
The FDA granted a supplemental approval for Flonase Sensimist Allergy Relief (fluticasone furoate) manufactured by Haleon US Holdings LLC.
-
FDA approval · 2023-11-15FDA Approved: CHILDRENS FLONASE ALLERGY RELIEF — Supplemental Application (Haleon US Holdings LLC)
The FDA approved a supplemental application for Children's Flonase Allergy Relief (fluticasone propionate) from Haleon US Holdings LLC.
-
FDA approval · 2023-11-09FDA Approved: CLARITIN-D 12 HOUR — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for Claritin-D 12 Hour (loratadine and pseudoephedrine sulfate) from Bayer HealthCare LLC. This acti…
-
FDA approval · 2023-11-09FDA Approved: CLARITIN-D 24 HOUR — Supplemental Application (Bayer HealthCare LLC.)
FDA approved Bayer’s supplemental application for Claritin-D 24 Hour, adding a 24-hour loratadine and pseudoephedrine sulfate formulation. T…
-
CLINICAL_TRIALS withdrawal · 2023-10-31Clinical Trial Update: Allergic Rhinitis Combination Pharmacotherapy Efficacy Study [Phase 4]
Phase 4 clinical trial for allergic rhinitis combination pharmacotherapy was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-10-30Clinical Trial Update: The Effects of OC000459 on Nasal Mediators [Phase 1, Phase 2]
Phase 1/2 trial evaluating OC000459 for allergic rhinitis has completed.
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis [Phase 2]
Phase 2 clinical trial investigating nasal irrigation with Chinese herbal medicine as an adjunctive treatment for allergic rhinitis has comp…
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract [Phase 2, Phase 3]
Clinical trial update for a Phase 2/3 study evaluating a polymerized, mannan-conjugated Dermatophagoides allergen extract for allergic rhini…
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis [Phase 2]
Phase 2 clinical trial update for CM310 in patients with uncontrolled seasonal allergic rhinitis.
-
CLINICAL_TRIALS withdrawal · 2023-10-16Clinical Trial Update: Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis [Phase 2, Phase 3]
Phase 2/3 clinical trial of chlorpheniramine maleate nasal spray for allergic rhinitis and nasal congestion was withdrawn.
-
FDA approval · 2023-10-13FDA Approved: LORATADINE — Supplemental Application (Wal-Mart Stores, Inc)
The FDA approved a supplemental application for loratadine submitted by Wal-Mart Stores, Inc. for an existing loratadine product.
-
CLINICAL_TRIALS trial_result · 2023-09-25Clinical Trial Update: A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis [Phase 2]
Phase 2 clinical trial evaluating the safety and effectiveness of a nasal spray for perennial allergic rhinitis has been completed.
-
FDA approval · 2023-09-21FDA Approved: MONTELUKAST — Supplemental Application (XLCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Montelukast from XLCare Pharmaceuticals Inc., authorizing a supplemental action related to a…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Diphenhydramine and Sweating [Phase 4]
A Phase 4 clinical trial update assessing diphenhydramine-related adverse effects including hyperthermia and sweating in therapeutic use.
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis. [Phase 2]
Phase 2 clinical trial investigating an IL4Rα monoclonal antibody for uncontrolled seasonal allergic rhinitis.
-
CLINICAL_TRIALS trial_result · 2023-09-08Clinical Trial Update: Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients [Phase 3]
Phase 3 trial update on AI201901 for allergic rhinitis has completed, reporting efficacy and safety data.
-
FDA label_change · 2023-08-29FDA Approved: RYALTRIS — Supplemental Application (HIKMA SPECIALTY USA INC.)
FDA approved a supplemental application for RYALTRIS (olopatadine hydrochloride and mometasone furoate) submitted by Hikma Specialty USA Inc…
-
FDA approval · 2023-08-08FDA Approved: FLUTICASONE PROPIONATE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for Fluticasone Propionate by Padagis Israel Pharmaceuticals Ltd, indicating an approved update to a…
-
FDA approval · 2023-07-31FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Montelukast Sodium from Macleods Pharmaceuticals Limited, authorizing continued marketing of thi…
-
FDA approval · 2023-07-28FDA Approved: LORATADINE — Original Application (Camber Consumer Care Inc)
The FDA approved Camber Consumer Care Inc's loratadine product via an Original Application (ANDA211718), providing a generic loratadine opti…
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: AllerPops Reduce Nasal Symptoms in Adult Volunteers With Allergic Rhinitis [Phase 2]
Phase 2 trial update suggesting AllerPops reduce nasal symptoms in adults with allergic rhinitis.
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Adolescent Mite Allergy Safety Evaluation [Phase 3]
Phase 3 safety evaluation for adolescents with mite allergy completed; results posted in 2023.
-
FDA approval · 2023-06-28FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental ANDA for Montelukast Sodium by Unichem Pharmaceuticals (USA), Inc., granting approval for its generic product. M…
-
FDA approval · 2023-06-12FDA Approved: AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for the azelastine hydrochloride and fluticasone propionate nasal spray from Padagis Israel Pharmace…
-
FDA approval · 2023-06-08FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Montelukast Sodium submitted by Camber Pharmaceuticals, Inc., under the approved ANDA.